4-溴-1-(二甲氧基甲基)-2-氟苯 | 439814-87-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-1-(二甲氧基甲基)-2-氟苯
• 中文别名: 4-溴-2-氟苯甲醛乙酸二甲酯；4-溴-1-二甲氧基甲基-2-氟苯
• 英文名称: 1-bromo-4-(dimethoxymethyl)-3-fluorobenzene
• 英文别名: 4-bromo-1-(dimethoxymethyl)-2-fluorobenzene；4-bromo-1-dimethoxymethyl-2-fluorobenzene
• CAS: 439814-87-6
• 化学式: C₉H₁₀BrFO₂
• 分子量: 249.08
• InChiKey: LUBJMTAUCIBGNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  4-溴-1-(二甲氧基甲基)-2-氟苯 在 palladium diacetate 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 N,N-二异丙基乙胺 、 sodium t-butanolate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 生成 N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-1-(2-fluorophenyl)methanesulfonamide
  参考文献：
  名称：

  Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action

  摘要：

  A minor structural change to tertiary sulfonamide RORc ligands led to distinct mechanisms of action. Co-crystal structures of two compounds revealed mechanistically consistent protein conformational changes. Optimized phenyl-sulfonamides were identified as RORc agonists while benzylsulfonamides exhibited potent inverse agonist activity. Compounds behaving as agonists in our biochemical assay also gave rise to an increased production of IL-17 in human PBMCs whereas inverse agonists led to significant suppression of IL-17 under the same assay conditions. The most potent inverse agonist compound showed >180-fold selectivity over the ROR isoforms as well as all other nuclear receptors that were profiled.

  DOI：

  10.1021/ml500420y
• 作为产物：
  描述：

  1,4-二溴-2-氟苯 在 正丁基锂 、 硫酸 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 2.0h， 生成 4-溴-1-(二甲氧基甲基)-2-氟苯
  参考文献：
  名称：

  功能化苯并硅氧烷的合成与转化

  摘要：

  报道了一系列带有合成有用的甲酰基和氰基的氟化苯并硅氧烷的合成和表征。这些化合物是通过从简单的卤代苯开始的多步合成获得的。一般的合成方案基于生成邻硼化芳基二甲基硅烷，由于相邻硼基团激活 Si-H 键，该硅烷在水解后发生脱氢环化。在某些情况下，相邻硼基和硅基官能团的协同作用导致 CHO 基团在温和的水性条件下发生意外的氢化硅烷化。在相对于硼原子的邻位带有甲酰基的苯并硅氧烷衍生物的还原导致结构转变，反映了碳硼杂环相对于其硅对应物的更高稳定性。因此，分离出一种独特的杂环系统，其特征在于包含两个硼硅氧烷键的中心 10 元环。

  DOI：

  10.1002/ejoc.201601328

文献信息

• [EN] BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS<br/>[FR] DÉRIVÉS DE BENZYLSULFONAMIDE UTILISÉS EN TANT QUE MODULATEUR DE RORC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013092941A1

  公开（公告）日：2013-06-27

  Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  式(I)的化合物或其药用可接受的盐，其中m、n、A、X1、X2、X3、X4、R1、R2、R3a、R3b、R4a和R4b的定义如本文所述。还公开了制备这些化合物的方法，并将这些化合物用于治疗炎症性疾病，如关节炎。
• Telomerase inhibitors and methods of their use
  申请人：——

  公开号：US20020120144A1

  公开（公告）日：2002-08-29

  Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are methods for assaying or screening for inhibitors of telomerase activity.

  本文提供了噻唑烷二酮化合物、组合物和方法，用于体外抑制端粒酶活性以及体内和体外治疗由端粒酶介导的疾病或病症。本发明的方法、化合物和组合物可以单独使用，也可以与其他药理活性剂结合在一起，用于治疗由端粒酶活性介导的疾病或病症，例如癌症的治疗。还公开了用于检测或筛选端粒酶活性抑制剂的方法。
• Therapeutic diphenyl ether ligands
  申请人：Fliri J. Anton

  公开号：US20060058361A1

  公开（公告）日：2006-03-16

  This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.

  该发明涉及式Ia、Ib或Ic的化合物，以及其药物组成物：或其前药和药用可接受载体，其中R基在规范中定义；以及虚线代表可选的双键。该发明还涉及治疗、诊断和预防与5HT受体相关的中枢神经系统疾病的方法，包括肥胖、注意缺陷障碍、偏头痛、抑郁症、癫痫、焦虑、阿尔茨海默病、戒毒、疼痛、精神分裂症、应激相关疾病、恐慌症、睡眠障碍、恐惧症、强迫症、创伤后应激综合征、免疫系统抑郁、应激引起的胃肠功能障碍、应激引起的心血管功能障碍和性功能障碍。
• BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS
  申请人：Genentech, Inc.

  公开号：US20130190288A1

  公开（公告）日：2013-07-25

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3a , R 3b , R 4a and R 4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  化合物I的公式或其药学上可接受的盐，其中m、n、A、X1、X2、X3、X4、R1、R2、R3a、R3b、R4a和R4b的定义如本文所述。还公开了制备该化合物的方法，并将该化合物用于治疗炎症性疾病，如关节炎。
• Aryl sulfamide and sulfamate derivatives as RORc modulators
  申请人：Genentech, Inc.

  公开号：US08912219B2

  公开（公告）日：2014-12-16

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  公式I的化合物或其药学上可接受的盐，其中m，n，p，q，r，A，X1，X2，X3，X4，X5，X6，Y，Z，G，R1a，R2a，R1b，R2b，R3，R4，R5和R6的定义如本文所述。还揭示了制备该化合物的方法，并将该化合物用于治疗炎症性疾病，如关节炎。